![neurostarlogo](https://www.guidancecenter.net/wp-content/uploads/2018/07/neurostarlogo-300x58.png)
Transcranial magnetic stimulation (TMS) uses a targeted pulsed magnetic field, similar to what is used in an MRI (magnetic resonance imaging) machine. While the patient is awake and alert, NeuroStar TMS Therapy stimulates areas of the brain that are under active in depression.
TMS Therapy is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.
TMS Therapy is only available by prescription. A doctor can help decide if TMS Therapy is right for you.
![neurostar](https://www.guidancecenter.net/wp-content/uploads/2018/07/neurostar-e1531949540896.jpg)
Transcranial magnetic stimulation (TMS) uses a targeted pulsed magnetic field, similar to what is used in an MRI (magnetic resonance imaging) machine. While the patient is awake and alert, NeuroStar TMS Therapy stimulates areas of the brain that are underactive in depression.5
In-office treatment with NeuroStar TMS Therapy takes 19-37 minutes and is administered 5 days a week for approximately 4-6 weeks.*
NeuroStar Advanced Therapy (TMS) is safe and easy to tolerate. Because it is not a depression drug, NeuroStar TMS Therapy does not have the same side effects that are associated with traditional antidepressant medications. More than 1.6 million treatments have been performed with NeuroStar, further proving its safety and tolerability record.
NeuroStar Advanced Therapy (TMS) for depression has the largest clinical data set of any TMS treatment. Clinical studies with over 900 people have shown that NeuroStar may help achieve remission for people living with depression.7, 8, 9, 10, 11, 13
For many people, depression symptoms significantly improved or went away after 4 to 6 weeks of treatment with NeuroStar Advanced Therapy.9
In an NIMH-funded, independent, randomized controlled trial, people treated with TMS using the NeuroStar Advanced Therapy, were four times more likely to achieve remission compared to patients receiving sham treatment
In an open-label trial 36.2% of patients received NeuroStar® Advanced Therapy reintroduction (average of 16 treatments). Long-term durability of effect has not been established in a randomized, controlled trial.
TMS was included in the 2010 American Psychiatric Association (APA) Practice Guideline for the Treatment of Patients with Major Depression—guidelines that provide recommendations for how psychiatrists treat depression.14